Phase 2a GNbAC1 mAb study in MS completes

If it's on your mind and it has to do with multiple sclerosis in any way, post it here.

Phase 2a GNbAC1 mAb study in MS completes

Postby MSUK » Mon Nov 04, 2013 3:39 am

GeNeuro announced today that its GNbAC1 humanized monoclonal antibody was found to have a very good safety profile when administered to patients with relapsing and progressive forms of Multiple Sclerosis as part of a Phase 2a study. GNbaC1 is a first-in-class monoclonal antibody targeting a toxic protein of endogenous retroviral origin that has been identified as a potential key factor in the onset and development of multiple sclerosis. Enrollment of patients into a multinational Phase 2b study is expected to begin during the first half 2014............ Read More - http://www.ms-uk.org/emergingtherapies
MS-UK - http://www.ms-uk.org/
User avatar
MSUK
Family Elder
 
Posts: 2180
Joined: Wed Oct 14, 2009 3:00 pm

Advertisement

Return to General Discussion

 


  • Related topics
    Replies
    Views
    Last post

Who is online

Users browsing this forum: No registered users


Contact us | Terms of Service